tutankhamuns
5年前
Qrons Inc.’s Jonah Meer Joins Everett Jolly on the Stock Day Podcast (QRON) November 5, 2019.
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydro gel, to treat penetrating brain injuries and QS200™, an inject able Ms Cs-synthetic hydro gel for the treatment of diffused injuries commonly referred to as concussions.
The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and in addition to the world-wide exclusive intellectual property license, a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, bio-compatible advanced materials. For additional information, please visit www.qrons.com.
LINK: https://stockdaymedia.com/news/radio-interviews/qrons-inc-s-jonah-meer-joins-everett-jolly-on-the-stock-day-podcast-qron-november-5-2019/
$QRON
tutankhamuns
5年前
Qrons Extends Sponsored Research Agreement with Dartmouth College
Supports Continued Research for the Development of Innovative 3D Printable, Biocompatible Advanced Materials, and Stem Cell Delivery Techniques for Traumatic Brain Injuries
NEW YORK, NY, Nov. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (TBIs) including concussions and penetrating injuries, today announced that it has extended the term of its Sponsored Research Agreement with Dartmouth College for an additional year with funding through July 14, 2020.
Professor Chenfeng Ke of the Chemistry Department at Dartmouth, and a member of the Qrons Scientific Advisory Board, will continue as the Principal Investigator for the sponsored research. Since July 2018, Qrons has been conducting research with Professor Ke to develop innovative 3D printable, biocompatible advanced materials as a component of its stem cell-based TBI treatment. In October 2019, Qrons entered into an Intellectual Property License Agreement with Dartmouth for an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. Professor Ke is also an inventor of the licensed 3D process.
Professor Chenfeng Ke commented, “Our project plan for the next year includes exploring a deeper level of integration of our hydrogels with cells and the surrounding environment to expand their adaptability for biomedical applications.”
Jonah Meer, Qrons' co-founder and CEO, added, "The extension of the Sponsored Research Agreement is a testament to the working relationship of our teams and the important work we’re doing together to improve the treatment of TBIs.”
"The importance of continuing our research with the team at Dartmouth cannot be overstated. We value our working relationship and are confident that we will continue to advance towards achievement of our goals,” concluded Ido Merfeld, Qrons’ co-founder, President and Head of Product.
About Dartmouth College
Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells ("MSCs") and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. For additional information, please visit www.qrons.com.
Forward Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518
LINK: http://www.globenewswire.com/news-release/2019/11/11/1944687/0/en/Qrons-Extends-Sponsored-Research-Agreement-with-Dartmouth-College.html
$QRON
tutankhamuns
5年前
Qrons is Developing 3D Printable Implants to Treat Brain Injuries
October 18, 2019 - by Vanesa Listek - 3D Printing - 3D Printing Materials - Medical 3D Printing
Every year traumatic brain injuries (TBI) affect an average of 69 million individuals worldwide. Although the number is less than one percent of the total global population, it is large enough to draw attention from researchers and companies trying to ease the pain and suffering related to the injury, which is usually the result of a fall, a sports injury and especially traffic accidents. In the United States, it is one of the leading causes of death and disability among children and young adults. With so many biotechnology companies springing up to resolve, via bioprinting, many common afflictions and diseases, one of them has been developing advanced stem cell-based solutions since 2016 to combat neuronal injuries, with a particular focus on TBI and concussions.
Qrons, headquartered in New York, is now going further with their innovative research after they announced an agreement with Dartmouth College, in New Hampshire, for an exclusive worldwide license to develop innovative 3D printable biocompatible materials to treat penetrating brain injuries, and more.
The agreement, signed October on 2, allows Qrons to use a patented 3D process entitled Mechanically Interlocked Molecules-based Materials for 3D Printing as part of its injury-specific 3D printable implants to treat penetrating brain injuries. Qrons is also a funding party to a sponsored research agreement with Dartmouth to advance the license or ownership of additional intellectual property, and the company’s research team is already working closely with Chenfeng Ke, the inventor of the licensed 3D process and an Assistant Professor at the university’s Department of Chemistry, to develop innovative 3D printable, biocompatible advanced materials.
Chenfeng Ke is currently leading the Ke Functional Materials Group Lab at Dartmouth, which focuses on syntheses and applications of polymeric materials for storage/separation and 3D printing applications. According to the lab, the research scheme overlaps organic synthesis, crystal engineering, polymer synthesis, materials characterization, and 3D printing, with an emphasis on the design of polymeric materials that are noncovalently assembled.
“We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries,” stated Ke, who is also a member of Qrons Scientific Advisory Board.
Today, current treatments to help patients regain function after a TBI focus on reducing secondary injuries, mainly rehabilitation in a hospital or specialized therapy center. It usually involves a physical therapist and occupational specialist to help patients relearn how to walk, talk, and carry out other everyday tasks. Qrons claims that this treatment can partially reduce further damage but do little or nothing to heal the brain.
At Qrons, researchers use a multi-disciplinary approach to treat this highly complex condition, by integrating a 3D printable, customized scaffold with innovative, engineered mesenchymal stem cells (MSCs) that target brain injuries to regenerate damaged tissue. The company suggests that these genetically modified MSCs offer a mechanism to secrete a continuous flow of neuro-protective and neuro-regenerative agents to drive TBI repair mechanisms. The agents can prevent further neuronal damage and have the potential to stimulate neurons to migrate to the injury site, regrow axonal processes and regenerate brain tissue.
Qrons already has two product candidates for treating TBIs, both integrating proprietary, modified MSCs and smart synthetic material. The QS100, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.
The exclusive worldwide license for 3D printable materials in the fields of human and animal health will enhance the company’s research, leading to further innovations in a niche field.
“The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries,” commented Ido Merfeld, Qrons Co-founder and Head of Product. “We believe combining Qrons’ proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.”
One of 111 bioprinting companies in the world, Qrons is moving fast to research novel techniques for promoting neural recovery. Throughout the last three years, they have entered into research agreements with Ariel University, based in Israel to develop and commercialize products for neuronal tissue regeneration and repair, completed the first in vivo animal experiments for the QS100 and are close to beginning pre-clinical experiments for the QS200.
Jonah Meer, also co-founder and CEO, said that “there is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.”
As the widespread impact of TBI continues to grow, solutions like the ones proposed by Qrons could mean a different lifestyle for survivors.
LINK: https://3dprint.com/256739/qrons-is-developing-3d-printable-implants-to-treat-brain-injuries/
$QRON
tutankhamuns
5年前
Qrons Granted Exclusive World-Wide License by Dartmouth College for Intellectual Property Related to 3D Printable Materials in Human and Animal Health
Qrons is Developing 3D Printable Implants to Treat Penetrating Brain Injuries
NEW YORK, NY, Oct. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has entered into an Intellectual Property License Agreement (the “Agreement”) with Dartmouth College for an exclusive world-wide license of Intellectual Property related to 3D printable materials in the fields of human and animal health. The Agreement provides for the payment by Qrons of initial and annual license fees and royalty payments based upon Qrons' product sales. The Agreement was signed on October 2, 2019 and is effective as of September 3, 2019.
Qrons is using the 3D process covered by the patent entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” as part of its injury specific 3D printable implants to treat penetrating brain injuries. Qrons is also a party to a Sponsored Research Agreement with Dartmouth to advance the license or ownership of additional Intellectual Property. The Qrons research team is working closely with Professor Chenfeng Ke, a member of Qrons Scientific Advisory Board and an inventor of the licensed 3D process, and PhD candidate Qianming Lin.
Ido Merfeld, Qrons Co-founder and Head of Product, commented, “The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries. We believe combining Qrons’ proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.”
Jonah Meer, Qrons’ Co-founder and CEO, added, “We’re excited to have concluded negotiations to acquire an exclusive license for this important intellectual property. There is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.”
Chenfeng Ke, Assistant Professor of Chemistry, Dartmouth College, stated, “We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries.”
Nila Bhakumi, Director of Technology Transfer at Dartmouth, echoed Professor Ke’s comments and added, “We are delighted with Dr. Ke’s collaboration with Qrons as they try to solve the very important problem of Traumatic Brain Injury.”
About Dartmouth College
Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells ("MSCs") and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.
The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and in addition to the world-wide exclusive intellectual property license, a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. For additional information, please visit www.qrons.com.
Forward Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518
LINK: https://www.globenewswire.com/news-release/2019/10/14/1929119/0/en/Qrons-Granted-Exclusive-World-Wide-License-by-Dartmouth-College-for-Intellectual-Property-Related-to-3D-Printable-Materials-in-Human-and-Animal-Health.html
$QRON
tutankhamuns
5年前
Qrons Announces Appointment of Derrick Chambers to Advisory Board
Sep 23, 2019 8:00 AM EDT
Former NFL Player is Financial Literacy Advocate to NFL Players Association and NFL Alumni Association
NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (“TBI”), including concussions and penetrating injuries, today announced that Derrick Chambers has been appointed to the Company’s Advisory Board, effective immediately.
Derrick Chambers, a former National Football League (“NFL”) defensive lineman for 3 years with the Carolina Panthers and the Jacksonville Jaguars, is a member of the National Football League Players Association and Alumni Association where he provides financial literacy and advisory services for professional athletes and entertainers. After the NFL, Mr. Chambers studied at the University of Oxford in England and at Oriel College Oxford. He continued his studies at the Princeton Theological Seminary, where he served as an Academic-Athletic fellow mentoring student athletes. He currently serves as a Board member of the Youth Leadership Foundation of Washington, D.C.
“We welcome Derrick Chambers to the Advisory Board of Qrons. Given his background as an NFL player and current role with the Players and Alumni Associations, he is acutely aware of the potential for Chronic Traumatic Encephalopathy, a progressive degenerative disease of the brain that results from repetitive concussions and is often found in longtime players of the sport. We look forward to his contributions and insight and his help raising awareness of Qrons’ potential for the treatment of traumatic brain injuries,” said Jonah Meer, CEO of Qrons.
Derrick Chambers added, “I believe that Qrons’ two product candidates have the potential to help the many chronic suffers of TBIs, a serious and degenerative condition that has no approved products for treatment. This is important work and I’m happy to join with them to raise awareness among my former colleagues and the community at large.”
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company has negotiated a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. For additional information, please visit http://www.qrons.com.
Forward Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518
LINK: https://www.morningstar.com/news/globe-newswire/7720505/qrons-announces-appointment-of-derrick-chambers-to-advisory-board
$QRON
tutankhamuns
5年前
Qrons to Present at the RHK Capital 4th Annual Disruptive Growth Conference Hosted by ReedSmith
Presentation on Thursday, September 5, 2019 at 9:00am EST
NEW YORK, NY, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it will be presenting at the 4th annual Disruptive Growth Conference on Thursday, September 5th at 9:00am EST. Jonah Meer, CEO, and John Bonfiglio, COO, will be presenting as well as meeting with investors.
The 2019 Disruptive Growth Conference will offer the exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel under which the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. For additional information, please visit http://www.qrons.com.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
About TAG Group:
TAG is part of the holding company TAG Group, Inc., a leading provider of estate, business and financial services for high net worth individuals and business entities. TAG maintains a comprehensive network of legal, financial and accounting professionals who are committed to providing the highest level of service to their clients. TAG maintains three separate and distinct operating units under its corporate umbrella, they are: Trust Advisory Group, Ltd., Advisory Group Equity Services, Ltd., and Estate Insurance Services, Ltd.
About Reed Smith:
Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our long-standing relationships and international outlook make us the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters. At Reed Smith, we believe that the practice of law has the ability to drive progress. We know your time is valuable and your matters are important. We are focused on outcomes, are highly collaborative, and have deep industry insight that, when coupled with our local market knowledge, allows us to anticipate and address your needs. You deserve purposeful, highly engaged client service that drives progress for your business.
Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518
LINK: https://www.globenewswire.com/news-release/2019/08/26/1906474/0/en/Qrons-to-Present-at-the-RHK-Capital-4th-Annual-Disruptive-Growth-Conference-Hosted-by-ReedSmith.html
$QRON
tutankhamuns
6年前
Qrons Selects PCG Advisory for Investor Relations and Strategic Communications as it Advances its Product Candidates
NEW YORK, NY,, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has retained PCG Advisory Inc., a leading investor relations and digital strategies firm, to provide investor relations, strategic communications and capital market advisory services.
Jonah Meer, Qrons' Chief Executive Officer, commented, "Qrons has developed two product candidates based on innovative technology using 3D printable, biocompatible advanced materials and a novel delivery system to reduce neuronal loss and functional impairment and induce neuronal regeneration and functional improvement in the treatment of traumatic brain injuries. We have also recently appointed Dr. John Bonfiglio as Chief Operating Officer to oversee our IND process in preparation for human clinical trials. We believe that PCG’s seasoned team, contacts, skills and strategies will assist us in communicating these important advancements to investors.”
Jeff Ramson, CEO of PCG Advisory, said; “Qrons’ work is important as there are currently no approved treatment options for traumatic brain injuries. Supported by the upgrade of Qrons’ common stock to the OTCQB Venture Market, we look forward to working with QRON to raise their awareness and visibility within the investment community.”
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel under which the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.
About PCG Advisory Inc.
Founded in 2008, PCG Advisory is dedicated to the delivery of top-tier strategic advisory services that encompass investor and stakeholder relations, capital markets navigation, corporate communications and social media management for emerging growth companies. The team at PCG has extensive experience with life science, fintech and blockchain technology and works with innovative and emerging companies from around the globe. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors and stakeholders in its proprietary and extensive distribution network, and through the use of unique digital marketing and audience development techniques. For more information, go to: www.pcgadvisory.com
Forward Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518
LINK: https://www.globenewswire.com/news-release/2019/08/19/1903508/0/en/Qrons-Selects-PCG-Advisory-for-Investor-Relations-and-Strategic-Communications-as-it-Advances-its-Product-Candidates.html
$QRON
tutankhamuns
6年前
Qrons Announces Upgrade to OTCQB Market
Trading Continues Under Ticker "QRON"
NEW YORK, NY, Aug. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON) an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that its common stock commenced trading today on the OTCQB Venture Market (OTCQB) after successfully upgrading from the Pink Market.
While Qrons has been a fully reporting company since its inception, the Company believes that the move to OTCQB will provide investor benefits including enhanced reporting standards, greater access to analyst coverage and news services, management certification and more comprehensive compliance requirements.
Jonah Meer, Qrons' Chief Executive Officer, commented, "We anticipate that the broader exposure afforded by the OTCQB Venture Market will raise our visibility within the investment community, assist in increasing the liquidity of our common stock and help to broaden our shareholder base. Upgrading to OTCQB is a significant milestone for any company, as it provides shareholders and potential investors with greater transparency and liquidity and will help generate exposure of our company to institutional investors.”
The OTCQB is a venture market designed for early-stage and developing US and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. To learn more, visit OTCQB at www.otcmarkets.com
About Qrons Inc.
Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.
Forward Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Contact:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080
LINK: https://www.globenewswire.com/news-release/2019/08/12/1900435/0/en/Qrons-Announces-Upgrade-to-OTCQB-Market.html
$QRON
tutankhamuns
6年前
OTC Markets Group Welcomes New OTCQB Companies – August 12
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the following company is approved for trading on the OTCQB Venture Market:
Qrons Inc. (OTCQB: QRON) The Company is an emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries (TBIs) and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100 an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200 an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company conducts its research in Israel under service agreements with Ariel University and has an ongoing Sponsored Research Agreement with Dartmouth College.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for this company on www.otcmarkets.com.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.
OTC Markets, OTCQX, OTCQB, Pink and OTC Link are registered trademarks of OTC Markets Group Inc.
LINK: http://www.publicnow.com/view/0617024D574B54204DE3C84EB7E98906238B7D71
$QRON
tutankhamuns
6年前
Dartmouth Launches Major Conference on 3D Printing’s Future
August 07, 2019
by Bill Platt
The gathering explores soft robotics, high-performance materials, and more.
Next week, Dartmouth will host one of the first international, interdisciplinary conferences on the future of “additive manufacturing,” the rapidly evolving field of 3D printing using advanced materials to create a spectrum of objects, such as artificial knee tendons, an implantable framework for brain neuron repair, soft-tissue robots, and performance-enhancing sneaker soles.
Assistant Professor of Chemistry Chenfeng Ke, an organizer of the conference, notes a certain kinship between this conference and the 1956 Dartmouth conference at which the term “artificial intelligence” was coined. The AI conference, like the upcoming 3D printing conference, was a gathering of the research community in a field on the cusp of new realms of discovery.
“The AI concept was cultivated here, so yes, in a similar way we want to cultivate some interdisciplinary collaborative thoughts in the area of additive manufacturing—AM,” Ke says. He hopes the symposium can become a regular event held every two years.
The two-day conference, to be held at the Hanover Inn Aug. 12 and 13, brings together researchers and scholars from the fields of chemistry, materials science, computer science, and engineering as well as industry players and entrepreneurs from across the United States, Europe, and Asia for “3D Printing 2019: An Interdisciplinary Additive Manufacturing Symposium.” Participants will look at a range of ideas in the field, including materials development, polymer chemistry, computational tools and models, green 3D printing, and 3D entrepreneurship. The talks and events on Monday afternoon, including a poster session and industry demonstration, are open to the public.
Until now, researchers in mechanical engineering, polymer and materials chemistry, computer science, and related fields have conferred separately to discuss 3D printing research, Ke says.
“There are separate meetings, but they don’t have cross talk, so we wanted to create this meeting to bring people with different expertise together, trying to connect from the very beginning—from the earliest computation and simulation, to the end-part of materials making and engineering,” Ke says.
The biomedical, printing materials, 3D printing technology, and 3D manufacturing industries as well as major publishing houses in the field are co-sponsors of the conference along with Dartmouth. Top scholars and researchers will make presentations at the conference, which will also include panel discussions and opening and closing sessions. In addition to Ke, the conference is co-chaired by Assistant Professor of Computer Science Bo Zhu, Adjunct Assistant Professor of Engineering Jeremy Faludi, and from the University of Texas at Dallas, Associate Professor of Chemistry Ronald Smaldone.
Ke’s own research uses carbohydrate-based printing materials he developed to create a tiny 3D architecture that can exist symbiotically with biological organisms on the cellular level. His lab is developing this material to enable 3D printing of structures such as artificial tissue scaffolds for treatment in traumatic brain injury.
“There are a lot of things you can play with in 3D printing, so that’s why we hope to inspire the different people who have different specialties and try to bring them together,” Ke says.
William Platt can be reached at william.c.platt@dartmouth.edu.
The graduate students in the Ke Laboratory sent a 3D model of the Dartmouth 250 logo to the 3D printer for a special demo. The case for the printer is tinted amber to block ultraviolet light when the printer is used to build bio-compatible structures for use in medical research. The actual printing project took about 40 minutes to complete. (Time-lapse video by Robert Gill)
LINK: https://news.dartmouth.edu/news/2019/08/dartmouth-launches-major-conference-3d-printings-future
$QRON
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Retire43
9月前
Philosophical Trader
4年前
